四川黄金公告，预计2025年度净利润为4.2亿元—4.8亿元，同比增长69.23%—93.40%。预计归属于上市 公司股东的净利润同比上升主要系金精矿销售量同比有所增加及黄金价格上涨所致。 ...

（文章来源：证券日报） 证券日报网讯 1月28日，商络电子发布公告称，公司预计2025年营业收入820000万元-900000万元，同 比增长25.28%-37.50%；归属于上市公司股东的净利润28500万元-31500万元，同比增长 302.55%-344.92%。 ...

思特威公告称，预计2025年度营收8.80-9.20亿元，同比增加2.83-3.23亿元，增幅47%-54%；归母净利润 9.76-10.31亿元，同比增加5.84-6.38亿元，增幅149%-162%；扣非归母净利润9.66-10.20亿元，同比增加 5.74-6.29亿元，增幅147%-161%。业绩增长得益于智能手机、汽车电子、智慧安防等领域业务提升。预 告未经审计，具体以2025年年度报告为准。 ...

证券日报网讯 1月16日，艾比森在互动平台回答投资者提问时表示，2025年度公司预计实现营业收入约 为41.56亿元，同比2024年上升约13.46%。其中：海外市场经过多年的持续深耕与科学布局，进一步深 化本地化运营，构建起高效协同的全球渠道网络，打造出差异化的品牌优势，显著增强了在国际市场的 竞争力。海外市场预计实现营业收入约31.93亿元，同比增长约8.94%，继续保持良好增长态势。国内市 场在LED显示整体需求疲软的背景下，通过聚焦优质客户、优化产品结构、调整渠道策略等关键举措， 预计实现营业收入约9.63亿元，同比增长约31.56%，成功实现逆势增长。更多详情请参阅已披露的业绩 预告。 （文章来源：证券日报） ...

格隆汇1月16日｜阳光诺和公告，公司预计2025年年度营业收入为119,245.48万元至137,132.31万元，与 上年同期相比，增加11,398.10万元至29,284.93万元，同比增长10.57%到27.15%。预计2025年利润总额 为19,578.57万元至23,494.28万元，与上年同期相比，增加1,979.84万元至5,895.55万元，同比增长 11.25%到33.50%。预计2025年年度实现归属于母公司所有者的净利润为19,105.21万元至22,926.25万 元，与上年同期相比，增加1,364.26万元至5,185.30万元，同比增长7.69%到29.23%。 ...

近期披露的业绩预告显示，公司预计2025年净利润为11亿元至16亿元，较上年同期增长127.31%至 230.63%。 粗看之下，增幅不算过于夸张，但是如果从业绩预告中位数来看，公司2025年四季度净利润达到9.3亿 元，同比、环比增幅均超过500%。 值得注意的是，天赐材料5日晚公告称，为保障后续液体六氟磷酸锂生产装置正常运行和安全稳定生 产，公司拟对龙山北基地年产15万吨液体六氟磷酸锂产线进行停产检修，预计检修时间为20天至30天。 公司已做好相关报批手续及材料准备，预计不会对公司经营情况造成较大影响。截至6日10：30左右， 天赐材料股价跌近2%，市值报958亿元。 天赐材料（002709）的业绩兑现能力，为卖方提供了极强的增长信心。 元旦期间，该公司2026年的卖方盈利预期值获得大幅上调，从去年11月初的最高值51亿元左右普遍上调 至80亿元左右，其中部分机构给出盈利预期值更是超过100亿元。 百亿盈利的前提 2025年，锂电材料整体"先跌后涨"，并于下半年完成筑底反弹。 其中，以六氟磷酸锂、碳酸亚乙烯酯（VC）为代表的电解液产业链产品，更是成为四季度表现最突出 的原材料之一。 其中，六氟磷酸锂出现翻 ...

Core Insights - The chairman of Mindray Medical, Li Xiting, completed a share buyback plan amounting to 200 million RMB, acquiring 1,005,381 shares, which represents 0.08% of the company's total shares [1][2] - The buyback was funded entirely by Li Xiting's personal funds, with a lock-up period of six months following the completion of the buyback [1] - Mindray Medical reported a year-on-year revenue growth of 1.53% in Q3 2025, indicating a turning point for the company [3] Group 1 - The buyback plan was initiated on November 27, 2025, with an average purchase price of 196.86 RMB per share, and was completed within 12 trading days [2] - The buyback reflects Li Xiting's confidence in the company's intrinsic value and future growth potential, aligning with the company's commitment to high-quality development in the capital market [2][3] - Mindray Medical has previously executed two share repurchase programs totaling 1 billion RMB each, demonstrating ongoing confidence in future growth [2] Group 2 - The company believes that the most challenging period for its domestic business has passed and is focusing on increasing market share, particularly in the IVD sector [4] - Mindray Medical is investing resources in high-value consumables and international markets, with significant growth potential in these areas [4] - The company aims to rank among the top 20 global medical device manufacturers, maintaining a leading market position in various product categories [4]

Core Insights - Yum China announced at its 2025 Investor Day that it expects system sales to achieve mid to high single-digit compound annual growth from 2026 to 2028, based on 2025 as the base year [1] - The company anticipates operating profit to achieve high single-digit compound annual growth during the same period [1] - Earnings per share and free cash flow per share are projected to achieve double-digit compound annual growth [1]

Investment Rating - The report maintains a "Buy-A" investment rating for the company with a 12-month target price of 15.84 CNY [4][5]. Core Views - The company reported a revenue of 1.601 billion CNY for the first three quarters of 2025, a decrease of 6.01% year-on-year, with a net profit attributable to shareholders of 190 million CNY, down 13.06% year-on-year [1]. - The explosive engineering segment saw significant growth, with revenue from this segment increasing by 114.92% year-on-year, despite declines in other product lines [2]. - The overall performance of the company is under pressure due to competitive challenges faced by its subsidiaries and a reduction in government subsidies compared to the previous year [3]. Summary by Sections Financial Performance - For Q3 2025, the company achieved a revenue of 543 million CNY, down 5.97% year-on-year, and a net profit of 69 million CNY, down 16.24% year-on-year [1]. - The sales of industrial explosives were 84,436.99 tons, a decrease of 2.63%, generating revenue of 521 million CNY, down 4.32% [2]. - The company’s gross margin for the first three quarters was 34.91%, an increase of 0.3 percentage points year-on-year, while the net margin was 11.83%, a decrease of 2.73 percentage points [2]. Future Projections - The projected net profits for 2025, 2026, and 2027 are 267 million CNY, 409 million CNY, and 504 million CNY, respectively, with growth rates of 47.9%, 53.1%, and 23.2% [4]. - The company is expected to maintain a price-to-earnings ratio of 24 times for 2026 [4]. Market Position - The company’s subsidiaries, particularly in the logistics and technology sectors, are experiencing performance fluctuations due to increased industry competition [3]. - The overall market environment is challenging, impacting the company's non-explosive business segments and leading to a decline in overall performance [3].

Core Viewpoint - Anta Sports (02020) reported a strong performance in the first half of the year, with revenue increasing by 14% year-on-year to RMB 38.544 billion, exceeding expectations [1] - The company is optimistic about achieving double-digit growth, adjusting its retail sales target for the Anta brand to the mid-single digits, supported by strong performances from all brands and stable results from Fila [1] Financial Performance - Revenue increased by 14% year-on-year to RMB 38.544 billion [1] - Gross profit rose by 13% year-on-year to RMB 24.425 billion [1] Future Outlook - The company is confident in achieving its double-digit growth target due to strong brand performance [1] - The target price for Anta Sports has been raised from HKD 108.6 to HKD 114.2, maintaining a "Buy" rating [1] - Earnings forecasts for the next two years have been increased by 1% and 3%, respectively, with revenue forecasts also raised by 3% each [1]